Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large study identifies genetic predictors of GLP-1 weight ...
China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...
Distinct GLP1R and GIPR variants correlated with nausea/vomiting risk, with a GIPR signal appearing tirzepatide-specific and showing markedly increased vomiting odds. New studies from 23andMe suggest ...
In this episode of Pharmaceutical Executive’s podcast series Leading Edge With Ken Banta, The Vanguard Network founder and ...
GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, and major pharmaceutical companies continue to introduce new versions of ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...
Prior to assuming her current role at AstraZeneca, Sarin was CFO at Alexion. In December 2020, AstraZeneca acquired Alexion, ...
Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...
In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results